Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients

ConclusionAnalyzing tumor‐derived biomarkers in platelets of CRPC patients enabled prediction of the outcome after abiraterone therapy with higher accuracy than baseline serum PSA or PSA response.

Source: The Prostate - November 2, 2017 Category: Urology & Nephrology Authors: Lee ‐Ann Tjon‐Kon‐Fat, Marie Lundholm, Mona Schröder, Thomas Wurdinger, Camilla Thellenberg‐Karlsson, Anders Widmark, Pernilla Wikström, Rolf Jonas Andreas Nilsson Tags: ORIGINAL ARTICLE Source Type: research